重型地中海贫血单倍体造血干细胞移植后细胞因子释放综合征临床特征分析

doi:10.7499/j.issn.1008-8830.2406036

摘要
图/表
参考文献(24)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (571 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的探讨重型地中海贫（thalassemia major, TM）患儿单倍体造血干细胞移植（haploidentical hematopoietic stem cell transplantation, haplo-HSCT）后细胞因子释放综合征（cytokine release syndrome, CRS）的发生特点及预后。方法回顾分析2019年1月—2021年12月在深圳市儿童医院血液肿瘤科采用haplo-HSCT的280例TM患儿，根据CRS标准分为CRS<3级组（260例）和CRS≥3级组（20例），分析TM患儿haplo-HSCT后CRS发生特点及预后。结果两组患儿在中性粒细胞植入时间、CRS临床表现、移植后4 d内糖皮质激素使用率之间的差异有统计学意义（P分别为0.012、0.040、<0.001）。CRS<3级组移植后3个月内急性移植物抗宿主病（acute graft versus host disease, aGVHD）发生率为9.6%，CRS≥3级组移植后3个月内未发生aGVHD，但两组移植后3个月内aGVHD发生率差异无统计学意义（P=0.146）。两组患儿haplo-HSCT后3个月内均未发生移植相关死亡。结论 CRS≥3级组患儿haplo-HSCT后中性粒细胞植入时间早、CRS临床表现重且多样，移植后4 d内糖皮质激素使用率高。CRS≥3级患儿移植后早期使用小剂量糖皮质激素可减轻CRS反应和减少aGVHD的发生，使患儿受益。haplo-HSCT后CRS对预后无显著影响。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周小辉
	王晓东
	林启洪
	王春静
	杨春兰
	李越
	张小玲
	张瑜
	余阅
	刘四喜

关键词 ：地中海贫血, 细胞因子释放综合征, 单倍体造血干细胞移植, 儿童

Abstract：Objective To investigate the clinical characteristics of cytokine release syndrome (CRS) in children with thalassemia major (TM) after haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and their prognosis. Methods A retrospective analysis was performed for the clinical data of 280 children with TM who underwent haplo-HSCT in the Department of Hematology and Oncology, Shenzhen Children's Hospital, from January 2019 to December 2021. According to the CRS criteria, they were divided into two groups: CRS grade <3 (260 children) and CRS grade ≥3 (20 children). The children with TM were analyzed in terms of clinical characteristics of CRS after haplo-HSCT and their prognosis. Results There were significant differences between the two groups in neutrophil engraftment time, clinical manifestations of CRS, and the rate of use of glucocorticoids within 4 days after haplo-HSCT (P=0.012, 0.040, and <0.001 respectively). For the CRS grade <3 group, the incidence rate of acute graft-versus-host disease (aGVHD) was 9.6% within 3 months after transplantation, while no aGVHD was observed in the CRS grade ≥3 group within 3 months after transplantation, but there was no significant difference in the incidence of aGVHD between the two groups within 3 months after transplantation (P=0.146). No transplantation-related death was observed in either group within 3 months after haplo-HSCT. Conclusions The children with CRS grade≥3 have an early neutrophil engraftment time, severe and diverse clinical manifestations of CRS, and a high rate of use of glucocorticoids within 4 days after haplo-HSCT. For these children, early use of low-dose glucocorticoids after transplantation may alleviate CRS response and reduce the incidence of aGVHD, thereby bringing more benefits to the children. CRS after haplo-HSCT has no significant impact on the prognosis of the children.

Key words： Thalassemia Cytokine release syndrome Haploidentical hematopoietic stem cell transplantation Child

收稿日期: 2024-06-07

基金资助:深圳市医疗卫生“三名工程”（SZSM202211033）；广东省高水平临床重点专科（SZGSP012）；深圳市医学重点学科建设经费资助（SZXK034）。

通讯作者: 刘四喜，男，主任医师。Email：tiger647@126.com。 E-mail: tiger647@126.com

作者简介: 周小辉，男，硕士，主治医师；

引用本文:

周小辉,王晓东,林启洪等. 重型地中海贫血单倍体造血干细胞移植后细胞因子释放综合征临床特征分析[J]. 中国当代儿科杂志, 2024, 26(12): 1301-1307.

ZHOU Xiao-Hui,WANG Xiao-Dong,LIN Qi-Hong et al. Clinical characteristics of cytokine release syndrome after haploidentical hematopoietic stem cell transplantation for thalassemia major[J]. CJCP, 2024, 26(12): 1301-1307.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2406036 或 http://www.zgddek.com/CN/Y2024/V26/I12/1301

	1 广东省地中海贫血防治协会, 《中国实用儿科杂志》编辑委员会. 造血干细胞移植治疗重型β地中海贫血儿科专家共识[J]. 中国实用儿科杂志, 2018, 33(12): 935-939. DOI: 10.19538/j.ek2018120602.
	2 中华医学会儿科学分会血液学组, 编辑委员会中华儿科杂志. 重型β地中海贫血的诊断和治疗指南（2017年版）[J]. 中华儿科杂志, 2018, 56(10): 724-729. DOI: 10.3760/cma.j.issn.0578-1310.2018.10.002.
	Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. PMID: 30592986. DOI: 10.1016/j.bbmt.2018.12.758.
	Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading[J]. Bone Marrow Transplant, 1995, 15(6): 825-828. PMID: 7581076.
	Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment[J]. Bone Marrow Transplant, 2018, 53(11): 1401-1415. PMID: 29872128. PMCID: PMC6786777. DOI: 10.1038/s41409-018-0204-7.
	Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J]. Nat Med, 2018, 24(6): 731-738. PMID: 29808005. PMCID: PMC6410714. DOI: 10.1038/s41591-018-0041-7.
	Nishimoto M, Hirose A, Koh H, et al. Clinical impacts of using serum IL-6 level as an indicator of cytokine release syndrome after HLA-haploidentical transplantation with post-transplantation cyclophosphamide[J]. Biol Blood Marrow Transplant, 2019, 25(10): 2061-2069. PMID: 31195139. DOI: 10.1016/j.bbmt.2019.06.003.
	Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation[J]. Biol Blood Marrow Transplant, 2019, 25(12): 2431-2437. PMID: 31394272. PMCID: PMC7402409. DOI: 10.1016/j.bbmt.2019.07.027.
	Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated[J]. Biol Blood Marrow Transplant, 2016, 22(10): 1851-1860. PMID: 27318038. PMCID: PMC5070661. DOI: 10.1016/j.bbmt.2016.06.010.
	Raj RV, Hamadani M, Szabo A, et al. Peripheral blood grafts for T cell-replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome[J]. Biol Blood Marrow Transplant, 2018, 24(8): 1664-1670. PMID: 29680516. DOI: 10.1016/j.bbmt.2018.04.010.
	Solán L, Landete E, Bailén R, et al. Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide[J]. Hematol Oncol, 2020, 38(4): 597-603. PMID: 32592410. DOI: 10.1002/hon.2772.
	Abboud R, Wan F, Mariotti J, et al. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis[J]. Bone Marrow Transplant, 2021, 56(11): 2763-2770. PMID: 34262142. DOI: 10.1038/s41409-021-01403-w.
	Knaus HA, Rottner T, Baumann CK, et al. Cytokine release syndrome during antithymocyte globulin/anti-T lymphocyte globulin serotherapy for graft-versus-host disease prophylaxis before allogeneic hematopoietic stem cell transplantation: incidence and early clinical impact according to American Society of Transplantation and Cellular Therapy grading criteria[J]. Transplant Cell Ther, 2022, 28(5): 260.e1-260.e9. PMID: 35217212. DOI: 10.1016/j.jtct.2022.02.016.
	Farias MG, de Mello Vicente B, Habigzang M, et al. High plasma IL-6 levels following haploidentical allogeneic hematopoietic stem cell transplantation post-transplant cyclophosphamide as predictor of early death and worse outcome[J]. Transpl Immunol, 2022, 71: 101543. PMID: 35093504. DOI: 10.1016/j.trim.2022.101543.
	Inoue T, Koyama M, Kaida K, et al. Peritransplant glucocorticoids redistribute donor T cells to the bone marrow and prevent relapse after haploidentical SCT[J]. JCI insight, 2021, 6(22): e153551. PMID: 34637399. PMCID: PMC8663779. DOI: 10.1172/jci.insight.153551.
	Wang S, Ai J, Cui P, et al. Diagnostic value and clinical application of next-generation sequencing for infections in immunosuppressed patients with corticosteroid therapy[J]. Ann Transl Med, 2020, 8(5): 227. PMID: 32309374. PMCID: PMC7154484. DOI: 10.21037/atm.2020.01.30.
	Davis TE, Kis-Toth K, Szanto A, et al. Glucocorticoids suppress T cell function by up-regulating microRNA-98[J]. Arthritis Rheum, 2013, 65(7): 1882-1890. PMID: 23575983. PMCID: PMC3713788. DOI: 10.1002/art.37966.
	Masouridi-Levrat S, Simonetta F, Chalandon Y. Immunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantation[J]. Front Immunol, 2016, 7: 362. PMID: 27695456. PMCID: PMC5025429. DOI: 10.3389/fimmu.2016.00362.
	Otoukesh S, Elmariah H, Yang D, et al. Cytokine release syndrome following peripheral blood stem cell haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide[J]. Transplant Cell Ther, 2022, 28(2): 111.e1-111.e8. PMID: 34844022. DOI: 10.1016/j.jtct.2021.11.012.
	McCurdy SR, Muth ST, Tsai HL, et al. Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes[J]. Biol Blood Marrow Transplant, 2018, 24(10): 2056-2064. PMID: 29909152. PMCID: PMC6385878. DOI: 10.1016/j.bbmt.2018.06.004.
	Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?[J]. Bone Marrow Transplant, 2007, 39(10): 577-588. PMID: 17369869. DOI: 10.1038/sj.bmt.1705616.
	Kurita N, Sakamoto T, Kato T, et al. Early administration of cyclosporine may reduce the incidence of cytokine release syndrome after HLA-haploidentical hematopoietic stem-cell transplantation with post-transplant cyclophosphamide[J]. Ann Hematol, 2021, 100(5): 1295-1301. PMID: 33580280. DOI: 10.1007/s00277-021-04439-6.
	Tang J, Jensen RR, Bryan B, et al. Reduced cytokine release syndrome and improved outcomes with earlier immunosuppressive therapy in haploidentical stem cell transplantation[J]. Transplant Cell Ther, 2024, 30(4): 438.e1-438.e11. PMID: 38281591. DOI: 10.1016/j.jtct.2024.01.076.
	Yao JM, Otoukesh S, Kim H, et al. Tocilizumab for cytokine release syndrome management after haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis[J]. Transplant Cell Ther, 2023, 29(8): 515.e1-515.e7. PMID: 37182736. PMCID: PMC10527340. DOI: 10.1016/j.jtct.2023.05.008.